GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Price-to-Free-Cash-Flow
中文

MannKind (MannKind) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 2004. Start your Free Trial

As of today (2024-04-23), MannKind's share price is $4.205. MannKind's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03. Hence, MannKind's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for MannKind's Price-to-Free-Cash-Flow or its related term are showing as below:

MNKD's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.29
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

MannKind's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 40.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 26.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 22.00% per year.

During the past 13 years, MannKind's highest 3-Year average Free Cash Flow per Share Growth Rate was 63.50% per year. The lowest was -33.70% per year. And the median was 27.80% per year.


MannKind Price-to-Free-Cash-Flow Historical Data

The historical data trend for MannKind's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MannKind Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, MannKind's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, MannKind's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MannKind's Price-to-Free-Cash-Flow falls into.



MannKind Price-to-Free-Cash-Flow Calculation

MannKind's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.205/-0.03
=N/A

MannKind's Share Price of today is $4.205.
MannKind's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

MannKind  (NAS:MNKD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


MannKind Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of MannKind's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind (MannKind) Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
Michael Castagna officer: Chief Commercial Officer 25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson officer: VP & Assoc General Counsel 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder officer: Chief Financial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank officer: EVP Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: EVP Chief Operating Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh officer: EVP Technical Operations 1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo officer: Chief Commercial Officer 30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross officer: Corp VP, Chief People Officer ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio director 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur director
Sabrina Kay director 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall officer: Chief Medical Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley officer: Chief Commercial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney officer: Chief Compliance Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362